Takehiko Okamura

Takehiko Okamura

Auto-generated profile, based on publicly available information

Takehiko Okamura

Department of Urology, Anjo Kosei Hospital, Japan

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Journal of Urology
Verified
Journal Article
Closed access
AYAkira Yokomizo
Akira Yokomizo
YKYusuke Kanimoto
Yusuke Kanimoto
TOTakehiko Okamura
Takehiko Okamura
SOSeiichiro Ozono
Seiichiro Ozono
HKHirofumi Koga
Hirofumi Koga
SNSeiji Naito
Seiji Naito
The optimal dose of intravesical bacillus Calmette-Guérin for the treatment of nonmuscle invasive bladder cancer is controversial. We investigated if induction therapy with low dose bacillus Calmette-Guérin could achieve a complete response rate similar to that of standard dose bacillus Calmette-Guérin, with less toxicity and higher quality of life. After transurethral resection, patients with unresectable multiple nonmuscle invasive bladder cancer and/or carcinoma in situ were randomized to receive standard (80 mg) or low dose (40 mg) bacillus Calmette-Guérin instillation induction therapy (weekly, 8 times). The primary end point was noninferiority of low dose bacillus Calmette-Guérin with a null hypothesis of a 15% decrease in complete response rate. Secondary end points were recurrence-free survival, progression-free survival, overall survival, patient compliance, adverse events and quality of life using the EORTC QLQ-C30. In an intent to treat analysis of 166 patients the complete response rates for low dose and standard dose bacillus Calmette-Guérin were 79% (95% CI 0.70-0.88) and 85% (95% CI 0.77-0.92), respectively. Dunnett-Gent analysis revealed that the null hypothesis of inferiority of low dose bacillus Calmette-Guérin in terms of complete response could not be rejected (p = 0.119). However, there were no significant differences between the groups in terms of recurrence, progression and overall survival. Low dose bacillus Calmette-Guérin was associated with significantly less fever (p = 0.001) and micturition pain (p = 0.047), and significantly higher quality of life scores for global quality of life, role functioning and functional impairment. The noninferiority of low dose bacillus Calmette-Guérin was not proven. However, low dose bacillus Calmette-Guérin was associated with lower toxicity and higher quality of life compared to standard dose bacillus Calmette-Guérin in patients with nonmuscle invasive bladder cancer.

13 December 2005 in The Prostate
Verified
Journal Article
Closed access
PDF file
SSShugo Suzuki
Shugo Suzuki
STSatoru Takahashi
Satoru Takahashi
STSeishiro Takahashi
Seishiro Takahashi
KTKentaro Takeshita
Kentaro Takeshita
AHAtsuya Hikosaka
Atsuya Hikosaka
TSTomoyuki Shirai
Tomoyuki Shirai

15 October 1984 in Cancer
Verified
Journal Article
Open access
PDF file
MOMikinobu Ohtani
Mikinobu Ohtani
SFShojl Fukushima
Shojl Fukushima
TOTakehiko Okamura
Takehiko Okamura
TSTakao Sakata
Takao Sakata
NINobuyuki Ito
Nobuyuki Ito
TNTadao Niijima
Tadao Niijima
The effects of intravesical instillation of Adriamycin (doxorubicin) (ADR), and mitomycin C (MMC), as inhibitors of development of rat bladder tumors, were examined in rats treated with N‐butyl‐N‐(4‐hydroxybuty1)nitrosamine (BBN). Intravesical instillation of ADR or MMC once a week for 12 weeks into rats pretreated with BBN for 4 weeks markedly enhanced development of bladder tumors. That is, one week after the end of intravesical instillation of these compounds the incidence of papillary or nodular hyperplasias, namely preneoplastic lesions, was significantly increased, and at the end of the experiment the incidence of not only papillary or nodular hyperplasias but also of papillomas and cancers was significantly increased. These results indicate that the intravesical instillation of ADR or MMC promotes two‐stage bladder carcinogenesis in rats.

1 September 1999 in Urologia Internationalis
Verified
Journal Article
Closed access
PDF file
KTKeiichi Tozawa
Keiichi Tozawa
YYYasuyuki Yamada
Yasuyuki Yamada
NKNoriyasu Kawai
Noriyasu Kawai
TOTakehiko Okamura
Takehiko Okamura
KUKosuke Ueda
Kosuke Ueda
KKKenjiro Kohri
Kenjiro Kohri
Objectives: Osteopontin (OPN), a secreted adhesive glycoprotein, has been shown to be produced in excessive amounts in a variety of experimental models of malignancy. Increased levels of OPN exist in blood from the lungs, breasts, and gastrointestinal tracts of cancer patients with metastases. However, there have been no reports on the expression of OPN in human urological malignancies. The present study investigates the presence of OPN in adenocarcinoma of the human prostate and in benign prostatic hyperplasia (BPH). Patients and Methods: Using prostate tissue from 34 patients with primary prostate cancer, 13 patients with prostate cancer after having undergone hormonal therapy, and 12 patients with BPH, formalin-fixed paraffin sections were prepared. Specimens were obtained by needle biopsy or radical prostatectomy. Immunohistochemical staining (ABC method) was then performed. Staining was divided into either negative or positive categories. Results: Positive staining of OPN was observed on cancer cells and macrophages in 52.9% of the primary prostate cancers and 14.5% of the prostate cancers after hormonal therapy. In BPH specimens, 66.7% of the cases displayed positive staining of OPN. The staining level of OPN showed no correlation with serum prostate-specific antigen, but did correlate with stage, differentiation, and Gleason’s score. Conclusions: The result postulates that the expression of OPN is an indicator of cell differentiation; however, it cannot be used as a marker of malignance in prostate cancer.

1 September 1996 in Journal of Urology
Verified
Journal Article
Closed access
TOTakehiko Okamura
Takehiko Okamura
KTKeiichi Tozawa
Keiichi Tozawa
YYYasuyuki Yamada
Yasuyuki Yamada
HSHiroshi Sakagami
Hiroshi Sakagami
KUKousuke Ueda
Kousuke Ueda
KKKenjiro Kohri
Kenjiro Kohri

11 June 2013 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
TNTaku Naiki
Taku Naiki
NKNoriyasu Kawai
Noriyasu Kawai
YHYoshihiro Hashimoto
Yoshihiro Hashimoto
TOTakehiko Okamura
Takehiko Okamura
RARyosuke Ando
Ryosuke Ando
KKKenjiro Kohri
Kenjiro Kohri